# Data on the correlation between hemostatic parameters before treatment start, and markers of fibrinolysis during treatment in patients with acute pulmonary embolism, undergoing ultrasound-assisted catheter-directed thrombolysis

## TL;DR

This study shows that pre-treatment blood markers can predict how well patients with pulmonary embolism will respond to a specific clot-dissolving therapy.

## Contribution

The paper provides new evidence that pre-treatment hemostatic parameters correlate with fibrinolytic response during ultrasound-assisted thrombolysis.

## Key findings

- Pre-treatment fibrinolytic markers correlate with the endogenous fibrinolytic response during treatment.
- Viscoelastic and plasma-based parameters predict individual treatment outcomes in pulmonary embolism patients.
- These findings support the potential use of these markers for personalized treatment adjustments in USAT.

## Abstract

Personalized medicine is nowadays increasingly being used to tailor therapies to the individual needs of patients [1]. We recently demonstrated, that various fibrinolytic parameters, including the plasma-based inducible plasmin-antiplasmin (plap) complex, as well as viscoelastic parameters, predict the individual treatment response in patients with intermediate- or high-risk pulmonary embolism (PE), treated with ultrasound-assisted catheter-directed thrombolysis (USAT) [2]. Markers of fibrinolysis and coagulation were assessed before the start of treatment (t0) and during the 10 - 15-hour infusion of recombinant tissue-type plasminogen activator (rt-PA) (t6). While we have already provided evidence of the predictive value of the assessed parameters for efficacy outcomes, in this article we present data on the correlation between these predictive markers and the endogenous fibrinolytic response during USAT. These data confirm the predictive value of the identified pre-treatment parameters for the endogenous treatment response, which may be important for their potential usefulness in modulating treatment decisions and dose adjustments in USAT for PE in the future.